An Unusual Presentation of Erythropoietin-Induced Acute Monoarthritis in a Patient With Myelodysplastic Syndrome and Behçet Disease: A Case Report
Erythropoiesis (EPO)-stimulating agents (ESAs) are recommended first-line therapy for symptomatic anemia in lower-risk myelodysplastic syndrome (MDS), reducing transfusion dependence in 40% to 60% of eligible patients.1 Arthralgia and myalgia are recognized side effects of ESAs,1 but evident inflammatory monoarthritis directly attributable to ESA therapy has not, to our knowledge, been previously reported.
Authors
- Lahsen Achemlal (ORCID: https://orcid.org/0000-0002-9744-1368)
- Jihad Moulay Berkchi (ORCID: https://orcid.org/0000-0002-8735-6880)
- Samia BELKHADIR
- Ilham Ouamer (ORCID: https://orcid.org/0009-0001-9874-0482)
Institutions
- Université Mohammed VI des Sciences et de la Santé (MA)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2026-11-15
- DOI
- https://doi.org/10.3899/jrheum.2026-0642
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00